Imugene logo
IMUImugene
Trade IMU now
Imugene primary media

About Imugene

Imugene (ASX:IMU) is a clinical-stage immuno-oncology company developing oncolytic virotherapies (OV) and T-cell receptor (TCR) therapies for the treatment of cancer. The company's OV platform is designed to selectively infect and replicate within cancer cells, while sparing healthy cells. Imugene's TCR therapy platform is designed to engineer T cells to recognize and kill specific cancer cells.

What is IMU known for?

Snapshot

Public AU
Ownership
2012
Year founded
59
Employees
New South Wales, Australia
Head office
1 of 246
AU Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Australia

Products and/or services of Imugene

  • Oncolytic virotherapy (OV) CF33: CF33 is a proprietary OV that selectively infects and replicates within cancer cells, while sparing healthy cells. CF33 is currently in Phase 2 clinical trials for the treatment of gastric cancer and head and neck cancer.
  • Oncolytic virotherapy (OV) VAXINIA: VAXINIA is a proprietary OV that is being developed for the treatment of solid tumors. VAXINIA is currently in Phase 1 clinical trials for the treatment of non-small cell lung cancer.
  • Oncolytic virotherapy (OV) HER-V: HER-V is a proprietary OV that is being developed for the treatment of breast and gastric cancers. HER-V is currently in Phase 1 clinical trials.
  • T-cell receptor (TCR) therapy targeting NY-ESO-1: Imugene's TCR therapy targeting NY-ESO-1 is being developed for the treatment of a variety of solid tumors that express NY-ESO-1. Imugene's TCR therapy targeting NY-ESO-1 is currently in Phase 1 clinical trials.
  • Personalized cancer vaccines: Imugene is developing personalized cancer vaccines that are designed to induce an immune response against the patient's own tumor. Imugene's personalized cancer vaccines are currently in preclinical development.
  • CAR T-cell therapy: Imugene is developing a CAR T-cell therapy for the treatment of B-cell lymphoma. Imugene's CAR T-cell therapy is currently in preclinical development.

Imugene executive team

  • Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDExecutive Chairman
  • Ms. Leslie ChongCEO, MD & Executive Director
  • Mr. Darren Michael Keamy B.Com., CPACFO & Company Secretary
  • Dr. John Byon M.D., Ph.D.Chief Medical Officer
  • Ms. Ursula McCurryChief Clinical Operations Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.